within Pharmacolibrary.Drugs.L_AntineoplasticAndImmunomodulatingAgents.L01F_MonoclonalAntibodiesAndAntibodyDrugConjugates.L01FE03_Necitumumab;
model Necitumumab 
   extends Pharmacolibrary.Drugs.ATC.L.L01FE03;

  annotation(Documentation(
    info ="<html><body><p>Necitumumab is a recombinant human IgG1 monoclonal antibody that binds to and inhibits the epidermal growth factor receptor (EGFR). It is used for the treatment of metastatic squamous non-small cell lung cancer (NSCLC) in combination with chemotherapy. Necitumumab was approved by the FDA in 2015 for this indication.</p><h4>Pharmacokinetics</h4><p>Pharmacokinetics reported in adult patients with advanced solid tumors and squamous NSCLC; population PK analysis.</p><h4>References</h4><ol><li><p>Dienstmann, R, &amp; Tabernero, J (2010). Necitumumab, a fully human IgG1 mAb directed against the EGFR for the potential treatment of cancer. <i>Current opinion in investigational drugs (London, England : 2000)</i> 11(12) 1434–1441. PUBMED:<a href=&quot;https://pubmed.ncbi.nlm.nih.gov/21154125/&quot;>https://pubmed.ncbi.nlm.nih.gov/21154125</a></p></li><li><p>Reichert, JM (2015). Antibodies to watch in 2015. <i>mAbs</i> 7(1) 1–8. DOI:<a href=&quot;https://doi.org/10.4161/19420862.2015.988944&quot;>10.4161/19420862.2015.988944</a>  PUBMED:<a href=&quot;https://pubmed.ncbi.nlm.nih.gov/25484055/&quot;>https://pubmed.ncbi.nlm.nih.gov/25484055</a></p></li></ol></body></html>",
    revisions = "<html><body><ul><li>06/2025 model generated by LLM gpt-4.1, references by scholarly and scripts created by Tomas Kulhanek</li></ul></body></html>",
    experiment(StartTime = 0, StopTime = 86400, Tolerance = 1e-09, Interval = 1)
  ));  
end Necitumumab;
